Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,080,288
  • Shares Outstanding, K 158,759
  • Annual Sales, $ 329,000 K
  • Annual Income, $ 23,380 K
  • EBIT $ 103 M
  • EBITDA $ 98 M
  • 60-Month Beta 2.01
  • Price/Sales 14.77
  • Price/Cash Flow 255.08
  • Price/Book 8.00

Options Overview Details

View History
  • Implied Volatility 62.70% (+8.62%)
  • Historical Volatility 40.53%
  • IV Percentile 42%
  • IV Rank 29.63%
  • IV High 111.36% on 07/10/25
  • IV Low 42.22% on 11/05/25
  • Expected Move (DTE 7) 1.54 (4.91%)
  • Put/Call Vol Ratio 0.31
  • Today's Volume 650
  • Volume Avg (30-Day) 2,149
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 89,389
  • Open Int (30-Day) 93,312
  • Expected Range 29.81 to 32.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.25
  • Number of Estimates 5
  • High Estimate 0.45
  • Low Estimate -0.17
  • Prior Year 0.15
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.50 +6.27%
on 12/10/25
33.78 -7.21%
on 11/26/25
+0.34 (+1.10%)
since 11/12/25
3-Month
29.50 +6.27%
on 12/10/25
37.55 -16.51%
on 10/01/25
-0.81 (-2.52%)
since 09/12/25
52-Week
25.28 +24.01%
on 08/11/25
46.48 -32.55%
on 05/01/25
+0.66 (+2.15%)
since 12/12/24

Most Recent Stories

More News
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8...

TGTX : 31.35 (-2.03%)
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX),   today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology,...

TGTX : 31.35 (-2.03%)
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the TD...

TGTX : 31.35 (-2.03%)
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 31.35 (-2.03%)
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI...

TGTX : 31.35 (-2.03%)
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the...

TGTX : 31.35 (-2.03%)
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated...

TGTX : 31.35 (-2.03%)
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI...

TGTX : 31.35 (-2.03%)
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in patients...

TGTX : 31.35 (-2.03%)
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy),...

TGTX : 31.35 (-2.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 33.22
2nd Resistance Point 32.76
1st Resistance Point 32.05
Last Price 31.35
1st Support Level 30.89
2nd Support Level 30.44
3rd Support Level 29.73

See More

52-Week High 46.48
Fibonacci 61.8% 38.38
Fibonacci 50% 35.88
Fibonacci 38.2% 33.38
Last Price 31.35
52-Week Low 25.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar